Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

ParameterAnalysed patients (N = 54)
Age (years), mean (SD)65.6 (5.9)
Male gender, n (%)38 (70)
Race, n (%)
 Caucasian53 (98)
 Asian1 (2)
BMI (kg/m2), mean (SD)26.2 (4.5)
Time since first COPD diagnosis (years), mean (SD)9.3 (4.7)
Smoking status at screening, n (%)
 Ex-smoker24 (44)
 Current smoker30 (56)
Post-bronchodilator FEV1 (L), mean (SD)1.46 (0.43)
Post-bronchodilator FEV1 (% predicted), mean (SD)50.1 (11.7)
 30 to < 50% predicted, n (%)26 (48)
 50 to 70% predicted, n (%)28 (52)
COPD Assessment Test, mean (SD)20.4 (6.0)
Sputum characteristics, mean (SD)
 Total cell count (× 106/g)4.6 (5.9)
 Neutrophil %82.4 (9.0)
 Macrophage %11.1 (7.5)
 Eosinophil %3.9 (4.4)
 Lymphocyte %0.2 (0.3)
 Epithelial cells %2.5 (3.7)
  1. Abbreviations: BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; FEV1, Forced expiratory volume in 1 s